What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?
Source : https://www.tandfonline.com/doi/full/10.1080/14656566.2022.2122710
Myasthenia gravis (MG) is a rare neurological disorder characterized by the impairment of the normal neuromuscular transmission. The majority of patients display antibodies directed either against the acetylcholine receptor (AChR), the muscle-specific kinase (MuSK) or the low-density lipoprotein receptor-related protein 4 (Lrp4). Finally, a small percentage of patients, defined as triple-seronegative, do not display any pathogenic autoantibody.
Expert Opinion: The recent introduction and continuous investigation of novel drugs targeting different immunopathological mechanisms raise the expectation of finally changing the algorithm of immunosuppression in MG. There is in fact a great unmet need in MG for a more effective and better tolerated therapy which could relieve the double burden given by the disease itself and the side effects due to chronic conventional immunosuppression, as well as respond to the non-negligible fraction of patients that do not respond or do not tolerate multiple immunosuppressants, including prednisone.